PD-L1/CD47 TUMOR DIRECTED B-BODYTM BISPECIFIC ANTIBODIES DEMONSTRATING SIGNIFICANT ANTITUMOR ACTIVITY WITH NO TOXICITY IN PRECLINICAL MODELS

被引：0

作者：

Kantak, Seema ^{[1
]}

Glaser, Bryan ^{[2
]}

Wetter, Justin ^{[2
]}

Sim, Bee-Cheng ^{[1
]}

Higaki, Jeff ^{[1
]}

Beal, Jacob ^{[2
]}

Ollerman, Sara ^{[2
]}

Pulukkunat, Dileep ^{[2
]}

Bawadekar, Mandar ^{[2
]}

Kaplan, Charles ^{[1
]}

Lamb, Peter ^{[1
]}

Hammer, Bonnie ^{[2
]}

机构：

[1] Exelixis Inc, Alameda, CA USA

[2] Invenra Inc, Madison, WI USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷

关键词：

D O I：

10.1136/jitc-2020-SITC2020.0630

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

630

引用

页码：A378 / A378

页数：1

共 50 条

[1] Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Wang, Yan
Ni, Haiqing
Zhou, Shuaixiang
He, Kaijie
Gao, Yarong
Wu, Weiwei
Wu, Min
Wu, Zhihai
Qiu, Xuan
Zhou, Ying
Chen, Bingliang
Pan, Donghui
Huang, Chenrong
Li, Mingzhu
Bian, Yicong
Yang, Min
Miao, Liyan
Liu, Junjian
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (02) : 365 - 376
[2] Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Yan Wang
Haiqing Ni
Shuaixiang Zhou
Kaijie He
Yarong Gao
Weiwei Wu
Min Wu
Zhihai Wu
Xuan Qiu
Ying Zhou
Bingliang Chen
Donghui Pan
Chenrong Huang
Mingzhu Li
Yicong Bian
Min Yang
Liyan Miao
Junjian Liu
Cancer Immunology, Immunotherapy, 2021, 70 : 365 - 376
[3] Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
Dheilly, Elie
Majocchi, Stefano
Moine, Valery
Didelot, Gerard
Broyer, Lucile
Calloud, Sebastien
Malinge, Pauline
Chatel, Laurence
Ferlin, Walter G.
Kosco-Vilbois, Marie H.
Fischer, Nicolas
Masternak, Krzysztof
ANTIBODIES, 2018, 7 (01):
[4] Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
Malinge, Pauline
Chauchet, Xavier
Bourguignon, Jeremie
Bosson, Nicolas
Calloud, Sebastien
Bautzova, Tereza
Borlet, Marie
Laursen, Mette
Kelpsas, Vinardas
Rose, Nadia
Gueneau, Franck
Ravn, Ulla
Magistrelli, Giovanni
Fischer, Nicolas
MABS, 2024, 16 (01)
[5] MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, Stephanie C.
Tong, Ling
Li, Yulin
Do, Rachel
Walz, Susanne
Fitzgerald, Kelly N.
Gouw, Arvin M.
Baylot, Virginie
Guetgemann, Ines
Eilers, Martin
Felsher, Dean W.
SCIENCE, 2016, 352 (6282) : 227 - 231
[6] Targeting CD47 enhanced the antitumor immunity of PD-L1 blockade in B-cell lymphoma
Nan, Yanyang
Zhang, Xuyao
Wang, Shaofei
Xu, Caili
Wang, Yichen
Han, Lei
Luan, Jingyun
Hu, Xiaozhi
Chen, Wei
Cao, Zhonglian
Zhu, Zeguo
Zeng, Xian
Fan, Jiajun
Ye, Li
Shi, Xunlong
Ju, Dianwen
IMMUNOTHERAPY, 2023, 15 (03) : 175 - 187
[7] IOH-001, a novel CD47/PD-L1 bispecific antibody, enhances anti-tumor activity in solid tumors
Kim, Jeong-kook
Jeon, A-Ra
Park, Jihyun
Choi, Ji Yea
Park, Ji Eun
Song, Sun Kwang
Choi, Ji Hye
Shin, Heewook
Lee, Ji Hye
Yun, Ji Hye
Ahn, Yoen Hee
Kim, Heung Tae
CANCER RESEARCH, 2022, 82 (12)
[8] Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
Chen, Shih-Hsun
Dominik, Pawel K.
Stanfield, Jessica
Ding, Sheng
Yang, Wenjing
Kurd, Nadia
Llewellyn, Ryan
Heyen, Jonathan
Wang, Carole
Melton, Zea
Van Blarcom, Thomas
Lindquist, Kevin C.
Chaparro-Riggers, Javier
Salek-Ardakani, Shahram
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
[9] Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression
Gong, Jianhua
Ji, Yuying
Liu, Xiujun
Zheng, Yanbo
Zhen, Yongsu
BIOCHEMICAL PHARMACOLOGY, 2022, 197
[10] A phase I study evaluating IMM2520 (CD47/PD-L1 bispecific molecule) in pts with advanced solid tumor
Sun, Y.
Yi, T.
Dang, Q.
Zhang, Y.
Ni, S.
Wu, A.
Zhao, X.
Wang, Z.
Lu, Q.
Tian, W.
ANNALS OF ONCOLOGY, 2024, 35 : S521 - S521

← 1 2 3 4 5 →